Related Experiment Video
Updated: Mar 14, 2026

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
Published on: July 26, 2018
Protection of cardiac cell-to-cell coupling attenuate myocardial remodeling and proarrhythmia induced by hypertension
T Egan Benova1, B Szeiffova Bacova, C Viczenczova
1Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovakia. tamara.benova@savba.sk.
Insights
Hypertension can cause heart problems by affecting connexin-43 channels. Certain supplements like melatonin and omega-3 fatty acids may protect the heart by improving connexin-43 function and preventing arrhythmias.
Area of Science:
- Cardiovascular Science
- Molecular Cardiology
Background:
- Gap junction connexin channels, particularly connexin-43, are vital for myocardial conduction and synchronized heart function.
- Hypertension is a major risk factor for cardiovascular events, including heart attack, heart failure, stroke, and sudden arrhythmic death.
- Hypertension-induced myocardial remodeling can lead to connexin-43 mislocalization and dysfunction, contributing to arrhythmias and heart failure.
Purpose of the Study:
- To investigate the role of connexin-43 abnormalities in hypertension-related cardiac dysfunction.
- To explore the cardioprotective and antiarrhythmic effects of non-pharmacological compounds in the context of hypertension.
Main Methods:
- Review of recent studies on connexin-43 in hypertension.
- Analysis of the impact of compounds like melatonin, omega-3 fatty acids, and red palm oil on myocardial connexin-43 and cardiac function in hypertensive models.
Main Results:
- Down-regulation, abnormal distribution, and altered phosphorylation of myocardial connexin-43 are implicated in hypertension-induced cardiac issues.
- Supplementation with melatonin, omega-3 fatty acids, and red palm oil demonstrated cardioprotective effects in hypertensive animals.
- These compounds attenuated connexin-43 abnormalities, preserved myocardial architecture, and improved cardiac conduction, leading to protection from lethal arrhythmias.
Conclusions:
- Novel mechanisms for the cardioprotective (antihypertensive and antiarrhythmic) effects of certain compounds have been uncovered.
- These findings highlight the potential of melatonin, omega-3 fatty acids, and red palm oil in managing hypertension-related cardiac complications.
- Further clinical trials are warranted to assess the antiarrhythmic potential of these compounds in hypertensive patients.
Abstract:
Gap junction connexin channels are important determinants of myocardial conduction and synchronization that is crucial for coordinated heart function. One of the main risk factors for cardiovascular events that results in heart attack, congestive heart failure, stroke as well as sudden arrhythmic death is hypertension. Mislocalization and/or dysfunction of specific connexin-43 channels due to hypertension-induced myocardial remodeling have been implicated in the occurrence of life-threatening arrhythmias and heart failure in both, humans as well as experimental animals. Recent studies suggest that down-regulation of myocardial connexin-43, its abnormal distribution and/or phosphorylation might be implicated in this process. On the other hand, treatment of hypertensive animals with cardioprotective drugs (e.g. statins) or supplementation with non-pharmacological compounds, such as melatonin, omega-3 fatty acids and red palm oil protects from lethal arrhythmias. The antiarrhythmic effects are attributed to the attenuation of myocardial connexin-43 abnormalities associated with preservation of myocardial architecture and improvement of cardiac conduction. Findings uncover novel mechanisms of cardioprotective (antihypertensive and antiarrhythmic) effects of compounds that are used in clinical settings. Well-designed trials are needed to explore the antiarrhythmic potential of these compounds in patients suffering from hypertension.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pathophysiology of Heart Failure
Mechanism of Cardiac Arrhythmias
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Antihypertensive Drugs: Action of β1 Blockers

